President Donald Trump predicted on Monday that Americans will witness the “largest tax refund season ever” this spring, crediting his administration's legislative reforms for a massive infusion of cash into household bank accounts. The ‘One Big Beautiful Bill Act' Legacy Speaking with Fox Business host Larry Kudlow, the President touted the success of the “One Big Beautiful Bill,” a comprehensive four-year legislative package passed earlier in his term. Trump emphasized that the bill was designed to str ...

Ethereum co-founder Vitalik Buterin has argued that hedging on prediction markets could provide the same kind of price stability as stablecoins, potentially rendering fiat currency unnecessary. In a long tweet, Buterin offered his views on how to make prediction markets more useful, with the Russian-Canadian programmer arguing that, while achieving a “high level” of success, they are currently producing an increasing quantity of “corposlop.” He wrote, “[Prediction markets] seem to be over-converging to a ...

Company Overview - TriMas is a diversified manufacturer with a global presence, focusing on packaging and aerospace fasteners, leveraging established brands and engineering expertise to meet evolving customer needs [6] - The company generates revenue primarily through the design, manufacture, and sale of proprietary and custom-engineered products for consumer, industrial, and aerospace applications [8] - Key customers include consumer product companies, aerospace original equipment manufacturers, industrial distributors, and commercial end-users worldwide [8] Financial Performance - TriMas reported revenue of $1.01 billion and net income of $44.08 million for the trailing twelve months (TTM) [4] - The company recently posted $269.3 million in third quarter sales, reflecting a 17.4% year-over-year increase, with adjusted diluted EPS rising 41.9% to $0.61 [10] - Adjusted operating profit increased 33.9% to $30.3 million, and year-to-date free cash flow reached $43.9 million, nearly quadrupling the prior year period [10] Stock Performance - As of February 12, 2026, shares of TriMas were priced at $35.75, up 51.4% over the past year, significantly outperforming the S&P 500 by 38.45 percentage points [7] - Following a sale of 143,900 shares, TriMas represents 3.05% of Barington Companies Management's reported U.S. equity assets under management [7] Market Position and Strategy - TriMas emphasizes innovation in its product lines and operational efficiency, supporting a competitive position in the packaging and industrial components sectors [6] - The company is positioned to benefit from aerospace and industrial recovery, with a focus on sustaining momentum in these sectors [11]

Dynatrace logo over a blue stock chart with green upward arrows, suggesting software shares rising after buybacks. Key Points The massive decline in software stocks, dubbed the "SaaS Apocalypse," has left many names deeply in the red during 2026. However, three software names are expressing confidence going forward, increasing their buyback capacity. Two names now have buyback authorizations equal to 9% or more of their market caps. Interested in Shopify Inc.? Here are five stocks we like better. T ...

Metaplanet became the latest Bitcoin-buying firm to acknowledge that its business came under pressure as the digital asset’s price plunged from record levels in October. On Monday, the Japanese firm disclosed a full-year loss of ¥95 billion, or $605 million, on ¥8.9 billion, or $58 million in revenue, according to an earnings presentation. The performance was largely driven by a decrease in the value of its 35,100 Bitcoin, which was worth $2.4 billion on Monday. Since it began accumulating Bitcoin 21 mont ...

Intel (NASDAQ: INTC) has served as a cautionary tale for investors about the perils of counting on a company to remain an industry leader. Intel reached peak prominence in the 1990s during the tech boom as the key producer of microprocessors for personal computers, but a series of miscues led Intel to let its leadership position slip out of its fingers. Now, the company is scurrying to catch up to rivals Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD), both of which have passed up Intel in ex ...

Quick Read iShares Silver Trust (SLV) surged 137% from February 2025 to February 2026. SLV climbed from $29.46 to $69.72. First Majestic Silver (AG) returned 304% over one year but trades at 164x trailing earnings. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Silver delivered one of the most explosive commodity performances of the past year, surging 137% from February 2025 to February 2026. The iS ...

The commercial real estate sector has delivered lackluster returns for the past few years. That's due to the impact higher interest rates have on commercial real estate. They increase interest expenses, cutting into a property's cash flow. Higher rates also make lower-risk fixed-income investments more attractive. These factors weigh on the value of commercial real estate. However, the Federal Reserve has started cutting interest rates, and more reductions could be forthcoming. That could drive a rebound ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside. As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts covering the stock, 10 assigned Buy ratings and 5 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $88.29, implying more than 47% upside. UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Susta ...

Summit Therapeutics (NASDAQ:SMMT) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish. The stock had received coverage from 6 analysts, 4 of whom had assigned Buy ratings and 2 gave Hold calls. With no Sell rating, the stock carries a projected median 1-year price target of $57.98, implying a strong upside of more than 296%. Adaptive Biotechnologies (ADPT) Hits 3-Year H ...